Momordica charantia nanoparticles potentiate insulin release and modulate antioxidant gene expression in pancreas of diabetic rats

Abstract

Abstract Background Green synthesis of nanoparticles with medicinal plants has inherent potential in the management of diabetes mellitus. This study synthesized Momordica charantia nanoparticles using silver nitrate to investigate the antidiabetic properties of this extract and the synthesized nanoparticles in vivo. Results The M. charantia nanoparticles used were synthesized biologically under ambient conditions from methanolic leaf extract of M. charantia using 1 mM concentration of aqueous silver nitrate and characterized using spectroscopic methods, FTIR and scanning electron microscopy. In vivo, the antidiabetic activity of M. charantia nanoparticle was assessed in streptozotocin-induced (65 mg/kg) rats. Rats were treated with M. charantia nanoparticle (50 mg/kg), aqueous leaf extract (100 mg/kg) metformin (100 mg/kg) and silver nitrate nanoparticle (10 mg/kg) for 21 days. Following treatment, rats were killed for biochemical analysis. Also, reverse transcript-polymerase chain reaction analyses of Takeda-G-protein-receptor-5, glucagon-like peptide-1, Insulin, superoxide dismutase, catalase and Nuclear factor-erythroid factor 2-related factor 2 (NRF2) - were carried out in the pancreas. A significant reduction in blood sugar levels was noted in rats treated with M. charantia nanoparticles. A reduction (p < 0.05) of pancreas alanine transaminase, aspartate aminotransferase and alkaline phosphatase was observed when compared with diabetic untreated rats. M. charantia nanoparticles significantly increase the antioxidant enzymes in diabetic rats when compared with diabetic untreated rats. The decrease in the level of triglyceride, cholesterol and low-density lipoprotein was observed when compared with diabetic control rats and also a significant increase in the expression of Takeda-G-protein-receptor-5, glucagon-like peptide-1, insulin, superoxide dismutase, catalase and NFE2-related factor 2 genes was observed when compared with diabetic untreated rats. Conclusions Momordica charantia nanoparticles exhibited potential antidiabetic activity in the rat model of diabetes and thus may serve as a therapeutic agent that could be developed for medical applications in the future.